CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that Curis scientists presented a poster entitled, “Anti-tumor activity of CUDC-101, a novel small molecule inhibitor of HDAC, EGFR and Her2, in hepatocellular cancer (HCC),” at the American Association for Cancer Research (AACR) Annual Meeting 2008, which is being held in San Diego, California, April 12-16.
